Multicentric Evaluation of COVID-19 Impact on Cancer Patients' Diagnostic and Management: Set-up of Indicators

NCT05932719 | Unknown

• 1 other identifier: 69HCL20_0697
• Study Type: observational
• Target: 4,000
• Locations: 1 country
• Sites: 1

Brief Summary

The COVID-19 pandemic has deeply and globally impacted usual procedures and patients management in cancer centers. The aim of this study is to set-up and collect indicators to follow-up the activities of different cancer pathologies before and during the pandemic. Patients loss' of chance will be analysed in term of diagnosis and access to care (surgery, antineoplastic treatments). Data collection will focus on the analysis of 2 specific pathologies for French patients in the "Auvergne-Rhône Alpes" Area: peritoneal carcinosis and hepatocellular carcinoma.

Conditions

Hepatocellular Carcinoma; Peritoneal Carcinoma

Keywords

COVID-19; Cancer; Health Care Quality Indicators; hepatocellular carcinoma; peritoneal carcinosis

Outcome Measures

Primary Outcomes (1)

• Measure of patient loss of chance when comparing a set of activity indicators between 2020 and the average activities of previous periods (2017-2019)

  The difference between a set of different activity indicators will be compared between 2020 and the average activities of previous periods (2017-2019)

  24 months

Study Arms (2)

Peritoneal Carcinosis

Patients hospitalized for peritoneal carcinosis between 2017 and 2020.

Other: COLLAT-COVID is an observational study based on retrospective data issued from patients medial files.

Hepatocellular Carcinoma

Patients hospitalized for hepatocellular carcinoma between 2017 and 2020.

Other: COLLAT-COVID is an observational study based on retrospective data issued from patients medial files.

Interventions

COLLAT-COVID is an observational study based on retrospective data issued from patients medial files. OTHER

The following items will be collected * Diagnostic date * Diagnostic stage * Date of surgery * Date of surgery appointment * First antineoplastic treatment date * Last antineoplastic treatment date * Number of treatment cycles recommanded by MDTM

Hepatocellular Carcinoma; Peritoneal Carcinosis

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients hospitalized in France for peritoneal carcinosis or hepatocellular carcinoma between 2017 and 2020.

You may qualify if:

• Patients hospitalized in France for peritoneal carcinosis or hepatocellular carcinoma between 2017 and 2020.

You may not qualify if:

• Patients who did not allow the reuse of their medical data for research

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

Study Sites (1)

Hopital Lyon sud, Hospices civils de Lyon

Pierre-Bénite, 69495, France

RECRUITING

MeSH Terms

Conditions

Carcinoma, Hepatocellular; COVID-19; Neoplasms

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 4, 2023
• First Posted: July 6, 2023
• Study Start: December 1, 2022
• Primary Completion: December 1, 2022
• Study Completion: December 1, 2024
• Last Updated: July 10, 2023

Record last verified: 2023-07

Locations

FR (1)